Drug intelligence / Profile preview

acyclovir + flucloxacillin

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular, Topical, Ophthalmic
01

Overview

Acyclovir + flucloxacillin is a combination of two pharmaceutical agents with distinct mechanisms of action. Acyclovir is an antiviral small molecule that acts as a guanosine analog, inhibiting viral DNA polymerase and thereby blocking replication of herpesviruses such as herpes simplex virus (HSV) and varicella zoster virus (VZV)[2]. Flucloxacillin is a narrow-spectrum beta-lactam antibiotic in the penicillin class, primarily active against Gram-positive bacteria including Staphylococcus aureus (excluding MRSA), by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins[7]. This combination may be considered in clinical scenarios where both viral (herpetic) and bacterial infections are suspected or confirmed. There are no known direct pharmacological interactions between these two drugs; they can be co-administered safely when clinically indicated[9].

Other names
acyclovir and flucloxacillinaciclovir + flucloxacillinaciclovir and flucloxacillin
02

Targets

Herpesvirus DNA polymerasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on acyclovir + flucloxacillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acyclovir + flucloxacillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call